Thu, April 11, 2013
[ Thu, Apr 11th 2013 ] - Market Wire
15 PM EDT
Wed, April 10, 2013
Tue, April 9, 2013
[ Tue, Apr 09th 2013 ] - Market Wire
30 a.m. ET
Mon, April 8, 2013
Sat, April 6, 2013
Fri, April 5, 2013
Thu, April 4, 2013
Wed, April 3, 2013
Tue, April 2, 2013
Mon, April 1, 2013
Fri, March 29, 2013
Thu, March 28, 2013
Wed, March 27, 2013
Tue, March 26, 2013
Mon, March 25, 2013
[ Mon, Mar 25th 2013 ] - Market Wire
Health Canada Decision Appealed
Sun, March 24, 2013
Fri, March 22, 2013
Thu, March 21, 2013
Wed, March 20, 2013
[ Wed, Mar 20th 2013 ] - Market Wire
00am ET
Tue, March 19, 2013
Mon, March 18, 2013
Sun, March 17, 2013
Fri, March 15, 2013
Thu, March 14, 2013

Merus Announces Annual General Meeting Results


//health-fitness.news-articles.net/content/2013/ .. us-announces-annual-general-meeting-results.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


March 29, 2013 12:00 ET

Merus Announces Annual General Meeting Results

TORONTO, ONTARIO--(Marketwire - March 29, 2013) -Merus Labs International Inc. ("Merus") (TSX:MSL)(NASDAQ:MSLI) announces the voting results from its Annual General Meeting of its shareholders held in Toronto.

A total of 11.9 million common shares representing 38.9% of Merus' issued and outstanding common shares were represented at the meeting. All of the shareholders present in person at the meeting voted in favour of the items of business and the overall result of the votes, including the votes by proxy, were as follows:

ResolutionForWithheld
Set Number of Directors at Six8,649,601106,140
Elect Elie Farah as a Director10,158,36131,991
Elect Ahmad Doroudian as a Director10,158,14132,211
Elect David Guebert as a Director7,381,9962,808,356
Elect Robert Pollock as a Director7,573,3362,617,016
Elect Joseph Rus as a Director10,158,23632,116
Elect Timothy Sorensen as a Director7,570,3362,620,016
Appoint Deloitte & Touche LLP as Auditors7,007,7026,505

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. Merus utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.




Publication Contributing Sources